How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.


Journal

PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404

Informations de publication

Date de publication:
02 2022
Historique:
accepted: 13 10 2021
pubmed: 6 11 2021
medline: 26 3 2022
entrez: 5 11 2021
Statut: ppublish

Résumé

Measuring and valuing health-related quality of life (HRQOL) in children can be challenging but is an important component for providing decision makers with accurate information to fund new interventions, including medicines and vaccines for public subsidy. We review funding submissions of medicines made to the Pharmaceutical Benefits Advisory Committee contained in public summary documents to examine the use of child-specific HRQOL measures in decision making in Australia. A sample frame of medicines used by children was derived from four sources. Public summary documents relating to these medicines were searched in the Pharmaceutical Benefits Advisory Committee web resources for whether they related to children (aged under 18 years) and contained HRQOL information and/or cost-utility analyses. Data about the use of utilities in decision making were extracted and analysed. Of the 1889 public summary documents available, 62 public summary documents (29 medicines) contained information pertaining to children and utilities. Of these, four public summary documents included child-specific HRQOL measures, 16 included adult HRQOL measures, 11 included direct elicitation and the HRQOL source was not defined in 31 documents. Excluding documents using child-specific HRQOL measures, we considered that in 85% of medicines, decision making uncertainty might have been reduced by using child-specific HRQOL measures. Despite the growing literature on economic analysis in paediatric populations, the use of child-specific HRQOL measures in submissions to the Pharmaceutical Benefits Advisory Committee was minimal. Submissions involved inconsistent approaches, use of adult measures and weights, and substantial gaps in evidence. We recommend the consistent use of child-specific measures to improve the evidence base for decisions about medicines for children in Australia.

Identifiants

pubmed: 34738210
doi: 10.1007/s40273-021-01107-5
pii: 10.1007/s40273-021-01107-5
pmc: PMC8794990
doi:

Substances chimiques

Pharmaceutical Preparations 0

Banques de données

figshare
['10.6084/m9.figshare.16807063']

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

157-182

Informations de copyright

© 2021. The Author(s).

Références

Med Care. 1996 Jul;34(7):702-22
pubmed: 8676608
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Clin Infect Dis. 2004 Dec 1;39(11):1572-80
pubmed: 15578353
Health Econ. 2003 Aug;12(8):697-702
pubmed: 12898666
Qual Life Res. 2018 Jul;27(7):1769-1780
pubmed: 29564713
Med Decis Making. 2011 Mar-Apr;31(2):281-91
pubmed: 20924045
Pharmacoeconomics. 2020 Apr;38(4):325-340
pubmed: 31903522
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Pediatrics. 2004 Feb;113(2):283-90
pubmed: 14754939

Auteurs

Cate Bailey (C)

Health Economics Unit, Melbourne School of Population and Global Health, University of Melbourne, 207 Bouverie St, Carlton 3053, Melbourne, VIC, Australia. cate.bailey@unimelb.edu.au.

Kim Dalziel (K)

Health Economics Unit, Melbourne School of Population and Global Health, University of Melbourne, 207 Bouverie St, Carlton 3053, Melbourne, VIC, Australia.

Paula Cronin (P)

Centre for Health Economics, Research and Evaluation (CHERE), University of Technology Sydney, Sydney, NSW, Australia.

Nancy Devlin (N)

Health Economics Unit, Melbourne School of Population and Global Health, University of Melbourne, 207 Bouverie St, Carlton 3053, Melbourne, VIC, Australia.

Rosalie Viney (R)

Centre for Health Economics, Research and Evaluation (CHERE), University of Technology Sydney, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH